Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia

被引：0

作者：

Becker, Pamela S. ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Div Leukemia, Duarte, CA 91010 USA

来源：

CANCER | 2025年 / 131卷 / 14期

基金：

美国国家卫生研究院;

关键词：

acute myeloid leukemia; allogeneic hematopoietic cell transplantation; chemotherapy; FMS-like tyrosine kinase 3 (FLT3); targeted inhibitor; RESIDUAL DISEASE; CHEMOTHERAPY; ADULTS;

D O I：

10.1002/cncr.35973

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 14 条

[1] A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia [J].

Bazinet, Alexandre ;

Bataller, Alex ;

Kadia, Tapan ;

Daver, Naval ;

Short, Nicholas J. ;

Yilmaz, Musa ;

Sasaki, Koji ;

Dinardo, Courtney D. ;

Borthakur, Gautam M. ;

Issa, Ghayas ;

Bouligny, Ian ;

Pierce, Sherry ;

Garcia-Manero, Guillermo ;

Ravandi, Farhad ;

Kantarjian, Hagop M. .

CANCER, 2025, 131 (06)

[2] getITD for FLT3-ITD-based MRD monitoring in AML [J].

Blaette, Tamara J. ;

Schmalbrock, Laura K. ;

Skambraks, Sabrina ;

Lux, Susanne ;

Cocciardi, Sibylle ;

Dolnik, Anna ;

Doehner, Hartmut ;

Doehner, Konstanze ;

Bullinger, Lars .

LEUKEMIA, 2019, 33 (10) :2535-2539

[3] DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant [J].

Dillon, Laura W. ;

Gui, Gege ;

Page, Kristin M. ;

Ravindra, Niveditha ;

Wong, Zoe C. ;

Andrew, Georgia ;

Mukherjee, Devdeep ;

Zeger, Scott L. ;

El Chaer, Firas ;

Spellman, Stephen ;

Howard, Alan ;

Chen, Karen ;

Auletta, Jeffery ;

Devine, Steven M. ;

Jimenez, Antonio Martin Jimenez ;

De Lima, Marcos J. G. ;

Litzow, Mark R. ;

Kebriaei, Partow ;

Saber, Wael ;

Weisdorf, Daniel J. ;

Hourigan, Christopher S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (09) :745-755

[4] Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML [J].

DiNardo, C. D. ;

Tiong, I. S. ;

Quaglieri, A. ;

MacRaild, S. ;

Loghavi, S. ;

Brown, F. C. ;

Thijssen, R. ;

Pomilio, G. ;

Ivey, A. ;

Salmon, J. M. ;

Glytsou, C. ;

Fleming, S. A. ;

Zhang, Q. ;

Ma, H. ;

Patel, K. P. ;

Kornblau, S. M. ;

Xu, Z. ;

Chua, C. C. ;

Chen, Xufeng ;

Blombery, P. ;

Flensburg, C. ;

Cummings, N. ;

Aifantis, I. ;

Kantarjian, H. ;

Huang, D. C. S. ;

Roberts, A. W. ;

Majewski, I. J. ;

Konopleva, M. ;

Wei, A. H. .

BLOOD, 2020, 135 (11) :791-803

[5] Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, doubleblind, placebo-controlled, phase 3 trial [J].

Erba, Harry P. ;

Montesinos, Pau ;

Kim, Hee-Je ;

Patkowska, Elzbieta ;

Vrhovac, Radovan ;

Zak, Pavel ;

Wang, Po -Nan ;

Mitov, Tsvetomir ;

Hanyok, James ;

Kamel, Yasser Mostafa ;

Rohrbach, Jaime E. Connolly ;

Liu, Li ;

Benzohra, Aziz ;

Lesegretain, Arnaud ;

Cortes, Jorge ;

Perl, Alexander E. ;

Sekeres, Mikkael A. ;

Dombret, Herve ;

Amadori, Sergio ;

Wang, Jianxiang ;

Levis, Mark J. ;

Schlenk, Richard F. .

LANCET, 2023, 401 (10388) :1571-1583

[6] Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].

Fröhling, S ;

Schlenk, RF ;

Breitruck, J ;

Benner, A ;

Kreitmeier, S ;

Tobis, K ;

Döhner, H ;

Döhner, K .

BLOOD, 2002, 100 (13) :4372-4380

[7] Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 [J].

Levis, Mark J. ;

Hamadani, Mehdi ;

Logan, Brent ;

Jones, Richard J. ;

Singh, Anurag K. ;

Litzow, Mark ;

Wingard, John R. ;

Papadopoulos, Esperanza B. ;

Perl, Alexander E. ;

Soiffer, Robert J. ;

Ustun, Celalettin ;

Ueda Oshima, Masumi ;

Uy, Geoffrey L. ;

Waller, Edmund K. ;

Vasu, Sumithra ;

Solh, Melhem ;

Mishra, Asmita ;

Muffly, Lori ;

Kim, Hee-Je ;

Mikesch, Jan-Henrik ;

Najima, Yuho ;

Onozawa, Masahiro ;

Thomson, Kirsty ;

Nagler, Arnon ;

Wei, Andrew H. ;

Marcucci, Guido ;

Geller, Nancy L. ;

Hasabou, Nahla ;

Delgado, David ;

Rosales, Matt ;

Hill, Jason ;

Gill, Stanley C. ;

Nuthethi, Rishita ;

King, Denise ;

Wittsack, Heather ;

Mendizabal, Adam ;

Devine, Steven M. ;

Horowitz, Mary M. ;

Chen, Yi-Bin .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (15) :1766-1775

[8] A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations [J].

Levis, Mark J. ;

Perl, Alexander E. ;

Altman, Jessica K. ;

Gocke, Christopher D. ;

Bahceci, Erkut ;

Hill, Jason ;

Liu, Chaofeng ;

Xie, Zhiyi ;

Carson, Andrew R. ;

McClain, Valerie ;

Stenzel, Timothy T. ;

Miller, Jeffrey E. .

BLOOD ADVANCES, 2018, 2 (08) :825-831

[9] Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome [J].

Loo, Sun ;

Dillon, Richard ;

Ivey, Adam ;

Anstee, Natasha S. ;

Othman, Jad ;

Tiong, Ing Soo ;

Potter, Nicola ;

Jovanovic, Jelena ;

Runglall, Manohursingh ;

Chong, Chyn Chua ;

Bajel, Ashish ;

Ritchie, David ;

Gray, Kelli ;

Yeoh, Zhi Han ;

McBean, Michelle ;

Gilkes, Amanda ;

Thomas, Ian ;

Johnson, Sean ;

Russell, Nigel H. ;

Wei, Andrew H. .

BLOOD, 2022, 140 (22) :2407-2411

[10] Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation [J].

Man, Cheuk Him ;

Fung, Tsz Kan ;

Ho, Christa ;

Han, Heron H. C. ;

Chow, Howard C. H. ;

Ma, Alvin C. H. ;

Choi, William W. L. ;

Lok, Si ;

Cheung, Alice M. S. ;

Eaves, Connie ;

Kwong, Yok Lam ;

Leung, Anskar Y. H. .

BLOOD, 2012, 119 (22) :5133-5143

← 1 2 →